1. Home
  2. PULM vs PCLA Comparison

PULM vs PCLA Comparison

Compare PULM & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PULM
  • PCLA
  • Stock Information
  • Founded
  • PULM 2003
  • PCLA 2008
  • Country
  • PULM United States
  • PCLA Japan
  • Employees
  • PULM N/A
  • PCLA N/A
  • Industry
  • PULM Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • PULM Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • PULM Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • PULM 30.9M
  • PCLA 32.3M
  • IPO Year
  • PULM N/A
  • PCLA 2025
  • Fundamental
  • Price
  • PULM $6.31
  • PCLA $0.55
  • Analyst Decision
  • PULM
  • PCLA
  • Analyst Count
  • PULM 0
  • PCLA 0
  • Target Price
  • PULM N/A
  • PCLA N/A
  • AVG Volume (30 Days)
  • PULM 19.7K
  • PCLA 119.3K
  • Earning Date
  • PULM 05-09-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • PULM N/A
  • PCLA N/A
  • EPS Growth
  • PULM N/A
  • PCLA N/A
  • EPS
  • PULM N/A
  • PCLA N/A
  • Revenue
  • PULM $7,806,000.00
  • PCLA $5,475,228.00
  • Revenue This Year
  • PULM N/A
  • PCLA N/A
  • Revenue Next Year
  • PULM $134.88
  • PCLA N/A
  • P/E Ratio
  • PULM N/A
  • PCLA N/A
  • Revenue Growth
  • PULM 6.96
  • PCLA 40.19
  • 52 Week Low
  • PULM $1.72
  • PCLA $0.46
  • 52 Week High
  • PULM $10.40
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • PULM 49.72
  • PCLA N/A
  • Support Level
  • PULM $5.31
  • PCLA N/A
  • Resistance Level
  • PULM $6.07
  • PCLA N/A
  • Average True Range (ATR)
  • PULM 0.50
  • PCLA 0.00
  • MACD
  • PULM 0.03
  • PCLA 0.00
  • Stochastic Oscillator
  • PULM 63.59
  • PCLA 0.00

About PULM Pulmatrix Inc.

Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: